Cargando…
Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967539/ https://www.ncbi.nlm.nih.gov/pubmed/35371464 http://dx.doi.org/10.1093/ckj/sfab258 |
| _version_ | 1784678863195865088 |
|---|---|
| author | Medina-Pestana, José Teixeira, Cinthia Montenegro Viana, Laila Almeida Manfredi, Silvia Regina Nakamura, Monica Rika Lucena, Elizabeth França Amiratti, Adriano Luiz Tedesco-Silva, Helio Covas, Dimas Tadeu Cristelli, Marina Pontello |
| author_facet | Medina-Pestana, José Teixeira, Cinthia Montenegro Viana, Laila Almeida Manfredi, Silvia Regina Nakamura, Monica Rika Lucena, Elizabeth França Amiratti, Adriano Luiz Tedesco-Silva, Helio Covas, Dimas Tadeu Cristelli, Marina Pontello |
| author_sort | Medina-Pestana, José |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8967539 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89675392022-03-31 Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study Medina-Pestana, José Teixeira, Cinthia Montenegro Viana, Laila Almeida Manfredi, Silvia Regina Nakamura, Monica Rika Lucena, Elizabeth França Amiratti, Adriano Luiz Tedesco-Silva, Helio Covas, Dimas Tadeu Cristelli, Marina Pontello Clin Kidney J Letter to the Editor Oxford University Press 2021-12-11 /pmc/articles/PMC8967539/ /pubmed/35371464 http://dx.doi.org/10.1093/ckj/sfab258 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Letter to the Editor Medina-Pestana, José Teixeira, Cinthia Montenegro Viana, Laila Almeida Manfredi, Silvia Regina Nakamura, Monica Rika Lucena, Elizabeth França Amiratti, Adriano Luiz Tedesco-Silva, Helio Covas, Dimas Tadeu Cristelli, Marina Pontello Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study |
| title | Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study |
| title_full | Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study |
| title_fullStr | Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study |
| title_full_unstemmed | Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study |
| title_short | Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study |
| title_sort | immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated coronavac vaccine among patients on dialysis: phase 4 study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967539/ https://www.ncbi.nlm.nih.gov/pubmed/35371464 http://dx.doi.org/10.1093/ckj/sfab258 |
| work_keys_str_mv | AT medinapestanajose immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT teixeiracinthiamontenegro immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT vianalailaalmeida immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT manfredisilviaregina immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT nakamuramonicarika immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT lucenaelizabethfranca immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT amirattiadrianoluiz immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT tedescosilvahelio immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT covasdimastadeu immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study AT cristellimarinapontello immunogenicityreactogenicityandbreakthroughinfectionsaftertwodosesoftheinactivatedcoronavacvaccineamongpatientsondialysisphase4study |